文献速递心律失常瓣膜病与结构性心脏病血脂与心血管预防

非维生素K拮抗剂口服抗凝药在房颤合并瓣膜性心脏病患者中的应用

Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

该荟萃分析纳入4项III期房颤试验,比较新型口服抗凝药(NOAC)与华法林在合并瓣膜性心脏病(VHD)患者中的相对风险和疗效。结果显示,高剂量NOAC在合并或不合并VHD的房颤患者中总体疗效和安全性相似。

要点

  • 高剂量NOAC降低卒中/系统性栓塞事件的风险在合并VHD患者(RR 0.70)与不合并VHD患者(RR 0.84)中一致。
  • 高剂量NOAC的大出血风险在合并VHD患者(RR 0.93)与不合并VHD患者(RR 0.85)中相似。
  • 高剂量NOAC降低颅内出血风险在合并VHD患者(RR 0.47)与不合并VHD患者(RR 0.49)中一致。

核心结论

  • 高剂量NOAC在合并或不合并VHD的房颤患者中提供总体相似的疗效和安全性。

研究设计与样本

  • 对4项比较目前可用NOAC与华法林的III期房颤试验进行荟萃分析,评估合并VHD患者的相对风险(RR)和95%置信区间(CI)。

主要发现

  • 高剂量NOAC相比华法林降低卒中/系统性栓塞事件的风险在合并VHD患者(RR 0.70;95% CI 0.58-0.86)与不合并VHD患者(RR 0.84;95% CI 0.75-0.95)中一致(交互作用P=0.13)。
  • 高剂量NOAC相比华法林的大出血风险在合并VHD患者(RR 0.93;95% CI 0.68-1.27)与不合并VHD患者(RR 0.85;95% CI 0.70-1.02)中相似(交互作用P=0.63)。
  • 高剂量NOAC相比华法林在合并VHD患者中未显示降低全因死亡的保护作用(RR 1.01;95% CI 0.90-1.14),而在不合并VHD患者中显示降低(RR 0.88;95% CI 0.82-0.94)(交互作用P=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist. Phase III trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral stenosis or mechanical heart valves, but variably included patients with other VHD and valve surgeries. OBJECTIVES: This study aimed to determine relative safety and efficacy of NOACs in patients with VHD. METHODS: We performed a meta-analysis of the 4 phase III AF trials of the currently available NOACs versus warfarin in patients with coexisting VHD to assess pooled estimates of relative risk (RR) and 95% confidence intervals (CIs) for stroke/systemic embolic events (SSEE), major bleeding, intracranial hemorrhage (ICH), and all-cause death. RESULTS: Compared with warfarin, the rate of SSEE in patients treated with higher-dose NOACs was lower and consistent among 13,585 patients with (RR: 0.70; 95% CI: 0.58 to 0.86) or 58,098 without VHD (RR: 0.84; 95% CI: 0.75 to 0.95; interaction p = 0.13). Major bleeding in patients on higher-dose NOACs versus warfarin was similar and consistent among patients with (RR: 0.93; 95% CI: 0.68 to 1.27) or without VHD (RR: 0.85; 95% CI: 0.70 to 1.02; interaction p = 0.63 for VHD/no-VHD difference). Intracranial hemorrhage was lower with higher-dose NOACs than with warfarin irrespective of VHD (RR: 0.47; 95% CI: 0.24 to 0.93, and 0.49; 95% CI: 0.41 to 059, respectively; interaction p = 0.91). No protective effect of higher-dose NOACs in preventing all-cause death seemed to be present in patients with VHD versus without VHD (RR:1.01; 95% CI: 0.90 to 1.14 vs. RR: 0.88; 95% CI: 0.82 to 0.94, respectively; interaction p = 0.03). CONCLUSIONS: High-dose NOACs provide overall efficacy and safety similar in AF patients with or without VHD.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Renda G, Ricci F, Giugliano RP, et al. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. J Am Coll Cardiol. 2017. PMID: 28302287. doi:10.1016/j.jacc.2016.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。